About Prof. Ye Shuang
Prof. Ye Shuang is a leading rheumatologist at Renji Hospital, Shanghai Jiao Tong University School of Medicine, specialising in systemic lupus erythematosus, rheumatoid arthritis, and autoimmune connective tissue diseases. Her team was the first to demonstrate that metformin significantly reduces SLE relapse risk, with results published in the New England Journal of Medicine and incorporated into international guidelines. She established the Shanghai Protocol for anti-MDA5 antibody-positive dermatomyositis, improving six-month survival from below 50% to 85% through early JAK inhibitor intervention, and her work on rituximab in refractory lupus nephritis has contributed to international treatment guidelines.
Case Overview
Ms. Tang (pseudonym), a 28-year-old woman, had been diagnosed with SLE three years earlier and had experienced two significant flares despite hydroxychloroquine, mycophenolate mofetil, and corticosteroids. At presentation she had nephrotic-range proteinuria (urine PCR 4.2 g/g), peripheral oedema, hypoalbuminaemia, and a SLEDAI-2K score of 14. Renal biopsy confirmed Class V (membranous) lupus nephritis. She had been on maximum-dose mycophenolate for 18 months without remission, and cumulative corticosteroid exposure was causing early cushingoid features and reduced bone density. Prof. Ye Shuang's multidisciplinary assessment formulated a two-phase strategy: rituximab-based B-cell depletion to achieve renal remission, followed by metformin maintenance to reduce relapse risk and allow corticosteroid tapering. Complete renal remission — proteinuria below 0.5 g/g with stable renal function — was achieved at month six. At two-year follow-up, Ms. Tang remained flare-free, prednisolone had been reduced to 5 mg daily, and proteinuria was 0.18 g/g. She reflected: "For two years I had been going from flare to flare, and every time the treatment made me feel worse even as it tried to make me better. Prof. Ye's team found a different approach — one that actually worked and that I could sustain. Two years without a flare is something I had stopped believing was possible."
Diagnostic Workup
Urinalysis and 24-hour urine protein quantification confirmed nephrotic-range proteinuria; urine microscopy identified red cell casts consistent with active nephritis. Serum creatinine, eGFR, albumin, complement C3 and C4, anti-dsDNA titre, and full blood count established the systemic disease activity profile. SLEDAI-2K scoring confirmed active multisystem disease at 14. Renal biopsy — light microscopy, immunofluorescence, and electron microscopy — confirmed Class V (membranous) lupus nephritis with subepithelial immune complex deposits; activity and chronicity indices were scored. B-cell subset analysis by flow cytometry established the baseline for rituximab response monitoring. DXA quantified corticosteroid-related bone loss. Multidisciplinary review — rheumatology, nephrology, and clinical pharmacology — confirmed the rituximab and metformin strategy.
Prof. Ye's pre-treatment assessment: Class V lupus nephritis reflects a different immunological mechanism from proliferative nephritis and requires a different therapeutic approach. Rituximab targets the B-cell compartment directly, depleting the cells that produce the pathogenic autoantibodies driving the membranous lesion. This patient's profile — refractory to maximum-dose mycophenolate, active membranous nephritis, high cumulative steroid burden — is exactly the profile in which rituximab is most likely to be effective. The metformin maintenance strategy addresses the relapse problem: our data show a 40% reduction in relapse risk, and it allows us to taper the steroids that are causing her the most harm.
Treatment Strategy and Course
Diagnosis: SLE with Class V (Membranous) Lupus Nephritis Refractory to Mycophenolate Mofetil, Nephrotic-Range Proteinuria, and Significant Corticosteroid Burden — 3-year SLE history, 28-year-old patient.
Treatment principle: two-phase precision immunotherapy — rituximab B-cell depletion to achieve renal remission, followed by metformin maintenance to reduce relapse risk and enable corticosteroid tapering.
- Phase 1 — Rituximab induction (Months 1–2): Rituximab 1000 mg IV on Days 1 and 15; well tolerated; B-cell depletion confirmed at Day 28 (CD19+ undetectable); mycophenolate continued at reduced dose
- Month 3 assessment: Proteinuria reduced to 1.8 g/g; albumin improved to 32 g/L; anti-dsDNA declining; complement C3 normalising; SLEDAI-2K 6; partial remission confirmed
- Month 6 — Complete renal remission: Proteinuria 0.42 g/g; albumin 38 g/L; eGFR stable; anti-dsDNA negative; complement normal; SLEDAI-2K 2
- Phase 2 — Metformin maintenance (Month 6 onwards): Metformin titrated to 1000 mg twice daily; prednisolone tapered from 15 mg to 5 mg daily over twelve months; mycophenolate continued at maintenance dose
- Two-year follow-up: No SLE flares; proteinuria 0.18 g/g; eGFR stable; anti-dsDNA negative; SLEDAI-2K 0; prednisolone 5 mg daily; bone density stable; patient returned to full-time work
Prof. Ye's clinical reflection: The rituximab result — complete renal remission in a patient who had failed 18 months of maximum-dose mycophenolate — confirms what the mechanistic rationale predicts: Class V nephritis is driven by B-cell-mediated autoantibody production, and depleting the B-cell compartment addresses the disease at its source. The metformin maintenance is the innovation that changes the long-term trajectory: a 40% reduction in relapse risk, achieved with a medication used safely for decades, that allows us to taper the steroids causing cumulative harm. Two years without a flare, on 5 mg of prednisolone — that is the outcome precision immunotherapy is designed to achieve.
Expert Commentary — Prof. Ye Shuang
1. Refractory Lupus Nephritis: Rituximab and B-Cell Targeted Therapy
Lupus nephritis affects approximately 50% of SLE patients and is the most important determinant of long-term morbidity and mortality. Standard first-line therapy achieves complete renal remission in approximately 30–40% of patients at six months, leaving a substantial proportion with persistent active nephritis. Class V (membranous) lupus nephritis is particularly challenging: the membranous pattern reflects subepithelial immune complex deposition driven by pathogenic autoantibodies, and responds less reliably to antiproliferative agents effective in proliferative nephritis. Rituximab — an anti-CD20 monoclonal antibody — depletes the B-cell populations responsible for autoantibody production, addressing the immunological mechanism of Class V nephritis directly. Prof. Ye Shuang's team has demonstrated a 30% improvement in complete remission rates in patients who have failed conventional immunosuppression, with results incorporated into international lupus nephritis treatment guidelines.
2. Metformin as a Relapse Prevention Strategy in SLE: The NEJM Evidence
Prof. Ye Shuang's team conducted a ten-year prospective study demonstrating that metformin reduces SLE flare frequency by approximately 40% compared with placebo, with a favourable safety profile. The biological mechanism involves metformin's activation of AMP-activated protein kinase (AMPK), which suppresses mTOR signalling and reduces the metabolic activity of autoreactive T and B cells — dampening immune dysregulation without the broad immunosuppression and toxicity of conventional agents. Published in the New England Journal of Medicine and incorporated into international SLE management guidelines, this finding established metformin as the first metabolic agent with proven efficacy in SLE maintenance therapy — a paradigm-shifting example of drug repurposing in autoimmune disease.
3. Precision Immunotherapy in SLE: Matching Biological Target to Disease Phenotype
SLE is a heterogeneous syndrome in which different patients are driven by different immunological mechanisms and respond differently to the same treatments. The precision immunotherapy framework — characterising the individual patient's immunological phenotype and selecting the biological agent targeting the dominant pathogenic pathway — is the approach most likely to achieve durable remission while minimising toxicity. In lupus nephritis, the distinction between proliferative (Class III/IV) and membranous (Class V) disease is the most clinically important phenotypic division: proliferative nephritis responds to antiproliferative agents; membranous nephritis responds to B-cell depletion. Beyond nephritis, specific autoantibody profiles and complement consumption patterns allow the clinician to anticipate organ involvement, predict flare risk, and select maintenance therapy accordingly. Prof. Ye Shuang's team has contributed to this precision framework through biomarker research, clinical trial participation, and the Renji Hospital rheumatology rare disease diagnostic platform, which integrates whole-exome sequencing for atypical presentations.
How CMCS Shanghai Coordinated This Case
CMCS Shanghai supported Ms. Tang throughout the diagnostic, treatment, and follow-up pathway at Renji Hospital, including: priority consultation coordination with Prof. Ye Shuang's rheumatology team; bilingual interpretation across all rheumatology and nephrology consultations and follow-up appointments; bilingual explanation of the Class V lupus nephritis diagnosis, rituximab treatment plan, and metformin maintenance strategy; coordination of renal biopsy, B-cell subset analysis, complement studies, anti-dsDNA monitoring, and DXA assessment with bilingual results communication; bilingual consent for rituximab and metformin; rituximab infusion day coordination including pre-medication and monitoring; ongoing follow-up coordination including proteinuria surveillance, B-cell reconstitution monitoring, corticosteroid taper scheduling, and SLEDAI-2K assessment.
For international patients with systemic lupus erythematosus, lupus nephritis, or other autoimmune connective tissue diseases, Prof. Ye Shuang's team at Renji Hospital offers access to one of China's most experienced and research-active rheumatology programmes. CMCS ensures that expertise is accessible — in the patient's language, with every step coordinated and communicated clearly.
This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.
0 Kommentare